BR112015005973A2 - derivado cumarínico - Google Patents

derivado cumarínico

Info

Publication number
BR112015005973A2
BR112015005973A2 BR112015005973A BR112015005973A BR112015005973A2 BR 112015005973 A2 BR112015005973 A2 BR 112015005973A2 BR 112015005973 A BR112015005973 A BR 112015005973A BR 112015005973 A BR112015005973 A BR 112015005973A BR 112015005973 A2 BR112015005973 A2 BR 112015005973A2
Authority
BR
Brazil
Prior art keywords
coumarin derivative
pharmaceutically acceptable
acceptable salt
active ingredient
inhibitory effect
Prior art date
Application number
BR112015005973A
Other languages
English (en)
Inventor
Sawada Kazuyoshi
Naiki Mitsuru
Ogino Takashi
Okada Tomoyuki
Original Assignee
Nippon Zoki Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co filed Critical Nippon Zoki Pharmaceutical Co
Publication of BR112015005973A2 publication Critical patent/BR112015005973A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

resumo patente de invenção: "derivado cumarínico". a presente invenção refere-se a um derivado cumarínico inovador ou a um sal farmaceuticamente aceitável do mesmo e também se refere a um agente farmacêutico que contém esse composto como um ingrediente ativo. o derivado cumarínico da presente invenção ou um sal farmaceuticamente aceitável do mesmo apresenta um excelente efeito de inibição para a destruição da cartilagem e efeito de inibição para a proliferação de células sinoviais em teste farmacológico onde a liberação de glicosamino glicanos sulfatados (sgag) e a proliferação de células sinoviais são usadas como indicadores por meio do qual é extremamente útil como um ingrediente ativo de uma composição farmacêutica tal como um agente de prevenção ou terapêutico para artropatia tal como osteoartrite ou artrite reumatoide crônica.
BR112015005973A 2012-09-21 2013-09-20 derivado cumarínico BR112015005973A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012208656 2012-09-21
PCT/JP2013/075414 WO2014046224A1 (ja) 2012-09-21 2013-09-20 クマリン誘導体

Publications (1)

Publication Number Publication Date
BR112015005973A2 true BR112015005973A2 (pt) 2017-07-04

Family

ID=50341526

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005973A BR112015005973A2 (pt) 2012-09-21 2013-09-20 derivado cumarínico

Country Status (15)

Country Link
US (1) US9365533B2 (pt)
EP (1) EP2899187B1 (pt)
JP (1) JP6091016B2 (pt)
KR (1) KR20150056544A (pt)
CN (1) CN104640849B (pt)
AU (1) AU2013318962B2 (pt)
BR (1) BR112015005973A2 (pt)
CA (1) CA2885262A1 (pt)
ES (1) ES2630068T3 (pt)
HK (1) HK1211918A1 (pt)
IL (1) IL237823A (pt)
RU (1) RU2646756C2 (pt)
SG (1) SG11201502149YA (pt)
TW (1) TWI583677B (pt)
WO (1) WO2014046224A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015141775A1 (ja) * 2014-03-20 2015-09-24 日本臓器製薬株式会社 クマリン誘導体を有効成分として含有する治療・予防剤
JP6089055B2 (ja) * 2014-03-20 2017-03-01 日本臓器製薬株式会社 クマリン誘導体を含有する医薬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1523317A (fr) * 1967-03-20 1968-05-03 Lipha Nouveaux dérivés hydroxylés de la coumarine et leurs procédés de préparation
FR2543140B1 (fr) * 1983-03-24 1985-06-21 Cortial Nouveaux acides flavone-carboxyliques-4', leur methode de preparation et leur application en therapeutique
RU2036917C1 (ru) * 1989-11-28 1995-06-09 Санкио Компани Лимитед Производные кумарина или их фармацевтически приемлемая соль
AU663057B2 (en) * 1990-09-28 1995-09-28 Pharmacia & Upjohn Company Anthelmintic and anticoccidal 3-carbamoyl-4-hydroxycoumarins
US5922755A (en) * 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
CN1204134C (zh) * 1996-05-15 2005-06-01 赫彻斯特股份公司 氨磺酰－取代的苯并二氢吡喃,其制法,作为药物或诊断剂的应用及含有它的药物
US6191164B1 (en) * 1996-05-15 2001-02-20 Hoechst Aktiengesellschaft Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
JP4658512B2 (ja) * 2004-04-27 2011-03-23 日本臓器製薬株式会社 クマリン誘導体及び該誘導体を含有するメイラード反応阻害剤
DE102004063910B4 (de) * 2004-07-05 2006-12-28 Bioplanta Arzneimittel Gmbh Trisubstituierte Benzopyranone sowie diese enthaltende Pflanzenextrakte und Mittel
KR101511396B1 (ko) * 2007-07-20 2015-04-13 추가이 세이야쿠 가부시키가이샤 ｐ27 단백질 유도제

Also Published As

Publication number Publication date
SG11201502149YA (en) 2015-05-28
EP2899187B1 (en) 2017-04-19
RU2015114480A (ru) 2016-11-10
JP6091016B2 (ja) 2017-03-08
TW201418239A (zh) 2014-05-16
US20150232440A1 (en) 2015-08-20
RU2646756C2 (ru) 2018-03-07
CN104640849A (zh) 2015-05-20
AU2013318962A1 (en) 2015-04-16
TWI583677B (zh) 2017-05-21
CA2885262A1 (en) 2014-03-27
KR20150056544A (ko) 2015-05-26
IL237823A (en) 2017-05-29
EP2899187A4 (en) 2016-06-29
ES2630068T3 (es) 2017-08-17
CN104640849B (zh) 2016-10-26
WO2014046224A1 (ja) 2014-03-27
EP2899187A1 (en) 2015-07-29
AU2013318962B2 (en) 2017-03-02
HK1211918A1 (en) 2016-06-03
US9365533B2 (en) 2016-06-14
JPWO2014046224A1 (ja) 2016-08-18

Similar Documents

Publication Publication Date Title
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112015014372A2 (pt) inibidores de autotaxina
BR112013019714A2 (pt) azaindolilfenil sulfonamidas como inibidores de serina/treonina quinase
BR112014030795A2 (pt) composto, composição farmacêutica, uso de um composto e processo para preparação de um composto
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
PH12014502040A1 (en) Heterocyclyl compounds
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201401351A1 (ru) Производные бензимидазол-пролина
BR112013031268A8 (pt) polipeptídeos
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
BRPI0924617A8 (pt) Compostos heterociclicos de fenoximetila
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
EA201490152A1 (ru) Антагонисты trpm8 и их применение при лечении
BR112016013425A2 (pt) Composto e composição farmacêutica
ECSP109968A (es) Depsipéptidos cíclicos
BR112014011254A2 (pt) 2-tiopirimidinonas
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CL2013002861A1 (es) Compuestos analogos de acido epoxieicosatrienoico, agonistas de eet; composicion farmaceutica; y uso de los compuestos para preparar medicamentos utiles para tratar hipertension y nefrotoxicidad inducida medicamentos, tal como cisplatino.
CL2014001704A1 (es) Derivados de amida ciclica como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa; composicion farmaceutica que los comprende y el uso de los mismos en la prevencion o tratamiento de enfermedades tales como la diabetes.
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.